MASCT-I

**MASCT-I** is an autologous, multi-antigen cellular cancer immunotherapy developed by HRYZ Biotech. The treatment is manufactured as sequential cellular products: antigen-loaded dendritic-cell vaccines intended to prime and expand tumor-reactive immunity, followed by adoptive infusion of autologous anti-tumor effector T cells. The antigen composition is not publicly specified, so MASCT-I is designed to generate immune responses against multiple tumor-associated antigens rather than one defined molecular target. In advanced soft tissue sarcoma, MASCT-I is being evaluated with doxorubicin and ifosfamide as first-line treatment in a Phase II study. MASCT-I has also been studied in advanced solid tumors and in bone and soft-tissue sarcomas in combination settings. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06277154))

Other names

Multi-antigen stimulated cell therapy-IMultiple antigen stimulating cellular therapy-IMultiple antigens specific cellular therapy